Significantly reduce blood lipids, innovative antisense oligonucleotide therapy reaches phase 2b clinical endpoint

On November 24, 2021, Ionis pharmaceuticals announced that vupanorsen, jointly developed with Pfizer, has reached primary and critical secondary clinical endpoints in phase 2b clinical trials

Vupanorsen used Ionis' Ligand-Coupled Antisense (LICA) technology to target the reduction of the key regulatory factor ANGPTL3 protein level in the liver

In a phase 2a trial, vupanorsen significantly reduced triglyceride levels in patients with hyperlipidemia, type 2 diabetes, and non-alcoholic fatty liver disease (NAFLD)

This multicenter, double-blind, controlled Phase 2b trial enrolled 286 dyslipidemia subjects (≥40 years old), defined as non-HDL-C (≥100 mg/dL) and TG (150-500 mg/dL) ) Is elevated and is receiving a stable dose of statin therapy

In terms of safety, the most common adverse event in the trial was injection site reaction, which occurred most often in the highest dose group

Reference materials:

[1] Ionis announces that Pfizer reports topline results from Phase 2b clinical study of vupanorsen.

(The original text has been deleted)